| First Author | Karthaus N | Year | 2014 |
| Journal | J Invest Dermatol | Volume | 134 |
| Issue | 5 | Pages | 1255-1264 |
| PubMed ID | 24352045 | Mgi Jnum | J:208055 |
| Mgi Id | MGI:5560844 | Doi | 10.1038/jid.2013.501 |
| Citation | Karthaus N, et al. (2014) Vitamin d controls murine and human plasmacytoid dendritic cell function. J Invest Dermatol 134(5):1255-64 |
| abstractText | Topical application of the vitamin D (VitD) analog calcipotriol is a highly effective standard treatment modality of psoriatic skin lesions. However, the immune modulatory effects of the treatment are incompletely understood. VitD is well known to induce tolerogenic responses in conventional dendritic cells (cDCs). Plasmacytoid DCs (pDCs) comprise a specialized, naturally occurring DC subset known to be important in autoimmune diseases including psoriasis. pDCs from the blood rapidly infiltrate psoriatic skin and are key to the initiation of the immune-mediated pathogenesis of the disease. We now demonstrate that pDCs express various proteins of the VitD receptor (VDR) pathway, including the VitD-metabolizing enzymes Cyp27B1 and Cyp24A1, and that VDR is transcriptionally active in pDCs. Moreover, VitD impairs the capacity of murine and human pDCs to induce T-cell proliferation and secretion of the T-helper 1 cytokine IFNgamma. The inhibitory effect of VitD is dependent on the expression of the VDR in the DCs. This study demonstrates that VitD signaling can act as a natural inhibitory mechanism on both cDCs and pDCs, which may instigate the development of VitD-based therapeutic applications for psoriasis and other inflammatory skin diseases. |
